[1]孟召伟,谭建.美国甲状腺协会和临床内分泌医师协会2012年甲减诊治指南介绍[J].国际放射医学核医学杂志,2013,37(2):124-127.[doi:10.3760/cma.j.issn.1673-4114.2013.02.016]
　MENG Zhao-wei,TAN Jian.Reading and analysis on management guidelines for hypothyroidism published in 2012 by American Thyroid Association and American Association of Clinical Endocrinologists[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):124-127.[doi:10.3760/cma.j.issn.1673-4114.2013.02.016]
点击复制

美国甲状腺协会和临床内分泌医师协会2012年甲减诊治指南介绍(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
37
期数:
2013年第2期
页码:
124-127
栏目:
综述
出版日期:
2013-03-25

文章信息/Info

Title:
Reading and analysis on management guidelines for hypothyroidism published in 2012 by American Thyroid Association and American Association of Clinical Endocrinologists
作者:
孟召伟;  谭建
天津医科大学总医院核医学科, 天津, 300052
Author(s):
MENG Zhao-wei;  TAN Jian
Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China
关键词:
甲状腺功能减退症; 促甲状腺素; 甲状腺素; 诊治指南
Keywords:
Hypothyroidism; Thyrotropin; Thyroxine; Diagnosis and treatment guideline
DOI:
10.3760/cma.j.issn.1673-4114.2013.02.016
摘要:
近期,美国甲状腺协会和临床内分泌医师协会联合发表了甲减诊治指南,该指南以循证医学为根据,对所涉及的15个方面的问题共提出了52条指南性的参考建议。该指南重点强调了促甲状腺激素对多数甲状腺功能减退症(甲减)患者的诊断价值,指出甲减的标准治疗方法是给予左旋甲状腺素,对于促甲状腺激素水平小于10mIU/L的亚临床甲减患者,需要根据患者的个体情况决定治疗方案。
Abstract:
Recently,American Thyroid Association and American Association of Clinical Endocrinologists published Clinical Huideline for Hypothyroidism.The authors took an evidence-based medicine approach,and created 52 recommendations on 15 issues.The guideline emphasized that serum thyrotropin is the single best screening test for primary thyroid dysfunction for the vast majority of outpatient clinical situations.The standard treatment for hypothyroidism is replacement with L-thyroxine.The decision to treat subclinical hypothyroidism when the serum thyrotropin is less than 10 mIU/L should be tailored to the individual patient.

参考文献/References:

[1] Bahn Chair RS,Burch HB,Cooper DS,et at.Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.Thyroid,2011,21(6):593-646.
[2] American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer,Cooper DS,Doherty GM,et al.Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.Thyroid,2009,19(11):1167-1214.
[3] Garber JR,Cobin RH,Gharib H,et al.Clinical practice guidelines for hypothyroidism in adults:cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association.Thyroid,2012,22(12):1200-1235.
[4] Toulis KA,Anastasilakis AD,Tzellos TG,et al.Selenium supplementation in the treatment of Hashimoto’s thyroiditis:a systematic review and a meta-analysis.Thyroid,201020(10):1163-1173.

相似文献/References:

[1]贾强,孟召伟,谭建.异位甲状腺发病机理、诊断与治疗的研究进展[J].国际放射医学核医学杂志,2016,40(4):297.[doi:10.3760/cma.j.issn.1673-4114.2016.04.012]
　Jia Qiang,Meng Zhaowei,Tan Jian.Progress of pathogenisis, diagnosis and treatment of ectopic thyroid[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):297.[doi:10.3760/cma.j.issn.1673-4114.2016.04.012]
[2]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
　Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[3]陈雪梅,周树云,范源,等.表没食子儿茶素没食子酸酯对131I辐射损伤所致甲减大鼠模型抗氧化体系的保护作用[J].国际放射医学核医学杂志,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
　Chen Xuemei,Zhou Shuyun,Fan Yuan,et al.Protection of antioxidant system of EGCG on the thyroid in rat model from 131I radiation damage[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
[4]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
　Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[5]程维维,王辉.促甲状腺激素受体与甲状腺癌关系的研究进展[J].国际放射医学核医学杂志,2012,36(2):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
　CHENG Wei-wei,WANG Hui.Progress in the relationship of thyroid-stimulating hormone receptor and thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
[6]黄丽娟,陈宁,叶静,等.反义肽核酸对促甲状腺激素受体mRNA表达的影响[J].国际放射医学核医学杂志,2012,36(5):310.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.011]
　HUANG Li-juan,CHEN Ning,YE Jing,et al.The effects of antisense peptide nucleic acid on the expression of thyroid stimulating hormone receptor mRNA[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):310.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.011]
[7]钟兴祥,郑吉祥,蓝冠章,等.Graves甲亢131I治疗前后血清TRAb动态变化及临床价值[J].国际放射医学核医学杂志,2011,35(2):110.[doi:10.3760/cma.j.issn.1673-4114.2011.02.011]
　ZHONG Xing-xiang,ZHENG Ji-xiang,LAN Guan-zhang,et al.Changes of serum TRAb after 131I radiotherapy in patients of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(2):110.[doi:10.3760/cma.j.issn.1673-4114.2011.02.011]
[8]王金萍,吴秋莲,徐浩.甲状腺功能与血清饥饿素和瘦素水平的相关陛研究[J].国际放射医学核医学杂志,2008,32(4):221.
　WANG Jin-Lian,WU Qiu-lion,XU Hao.Association of thyroid function with human serum ghrelin and leptin levels[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(2):221.
[9]李诗运,谭本旭,戴儒奇,等.优甲乐和稳定性碘干预131I致大鼠甲状腺功能减低的研究[J].国际放射医学核医学杂志,2007,31(6):325.
　LI Shi-yun,TAN Ben-xu,DAI Ru-qi,et al.Interventions of euthyrox and stable iodine in hypothyroid occurrence of rats treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(2):325.
[10]孟召伟,谭建.重组人促甲状腺激素和促再分化药物在分化型甲状腺癌中的应用[J].国际放射医学核医学杂志,2006,30(6):338.
　MENG Zhao-wei,TAN Jian.Application of recombinant human thyrotropin and redifferentiation drugs in differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(2):338.
[11]郭永铁.促甲状腺激素与亚临床性甲状腺功能异常[J].国际放射医学核医学杂志,2008,32(6):351.
　GUO Yong-tie.Thyroid stimulating hormone and subclinical thyroid dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(2):351.

备注/Memo

备注/Memo:
收稿日期:2013-01-11。
通讯作者:谭建,Email:tanpost@163.com
更新日期/Last Update: 1900-01-01